PLSE Pulse Biosciences, Inc.
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.…
Industry Peers
Medical Instruments & SuppliesKey Statistics
About Pulse Biosciences (NASDAQ: PLSE)
›
Pulse Biosciences (NASDAQ: PLSE) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 116 employees.
The shares were at 44.41 USD on 19 November 2026, up 173.0% over 52 weeks. Its 52-week range is 12.56 USD to 58.94 USD: the price is 24.7% below the high and 253.6% above the low.
Its market capitalisation is 3.27B USD.
Pulse Biosciences reports return on equity of -90.2% and revenue up 359.3% year over year.
It holds more cash than debt, a net cash position of 182.83M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 6 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 67.67 USD is 52.4% above the current price. The next earnings report is expected on 18 February 2027.